Sadia Khan

The mechanisms causing diabetes and heart failure are inextricably linked, as are the prognostic outcomes seen in these two complex disease processes. Treating both conditions together is absolutely vital to bring about the best long-term outcomes for patients. We have strong evidence-based therapies which have been shown to successfully treat both these conditions with improved prognosis and patient outcomes. The more recent development of SGLT2 inhibitors have further enhanced this clear clinical benefit for heart failure and diabetes combined. This is an exciting area of rapidly expanding research and further trials looking at these benefits are underway.